156 related articles for article (PubMed ID: 27141880)
21. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study.
El-Gazzar MG; El-Hazek RM; Zaher NH; El-Ghazaly MA
Bioorg Chem; 2019 Nov; 92():103251. PubMed ID: 31525526
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of tumor-induced angiogenesis and its mechanism by ardipusilloside I purified from Ardisia pusilla.
Wang R; Gu Y; Zhang WD; Yan XN; Jin L; Wang XJ
J Asian Nat Prod Res; 2012; 14(1):55-63. PubMed ID: 22263594
[TBL] [Abstract][Full Text] [Related]
23. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
Su M; Huang J; Li J; Qin X; Tang X; Jin F; Chen S; Jiang C; Zou Z; Peng K; Nuruzzaman M; Zhang J; Luo J; Liu S; Luo Z
Oncotarget; 2016 Apr; 7(14):19018-30. PubMed ID: 26967559
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents.
Tang Z; Wu C; Wang T; Lao K; Wang Y; Liu L; Muyaba M; Xu P; He C; Luo G; Qian Z; Niu S; Wang L; Wang Y; Xiao H; You Q; Xiang H
Eur J Med Chem; 2016 Aug; 118():328-39. PubMed ID: 27176944
[TBL] [Abstract][Full Text] [Related]
25. A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex--medicinal chemistry consequences of a TKs analysis.
Lintnerová L; García-Caballero M; Gregáň F; Melicherčík M; Quesada AR; Dobiaš J; Lác J; Sališová M; Boháč A
Eur J Med Chem; 2014 Jan; 72():146-59. PubMed ID: 24368209
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
[TBL] [Abstract][Full Text] [Related]
27. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
28. In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.
Latham AM; Kankanala J; Fearnley GW; Gage MC; Kearney MT; Homer-Vanniasinkam S; Wheatcroft SB; Fishwick CW; Ponnambalam S
PLoS One; 2014; 9(11):e110997. PubMed ID: 25393739
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Tang Z; Niu S; Liu F; Lao K; Miao J; Ji J; Wang X; Yan M; Zhang L; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2014 May; 24(9):2129-33. PubMed ID: 24721727
[TBL] [Abstract][Full Text] [Related]
30. Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity.
Christodoulou MS; Liekens S; Kasiotis KM; Haroutounian SA
Bioorg Med Chem; 2010 Jun; 18(12):4338-50. PubMed ID: 20493716
[TBL] [Abstract][Full Text] [Related]
31. Novel 5-(2-hydroxyphenyl)-3-substituted-2,3-dihydro-1,3,4-oxadiazole-2-thione derivatives: promising anticancer agents.
Aboraia AS; Abdel-Rahman HM; Mahfouz NM; El-Gendy MA
Bioorg Med Chem; 2006 Feb; 14(4):1236-46. PubMed ID: 16242340
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, thymidine phosphorylase inhibitory and computational study of novel 1,3,4-oxadiazole-2-thione derivatives as potential anticancer agents.
Bajaj S; Roy PP; Singh J
Comput Biol Chem; 2018 Oct; 76():151-160. PubMed ID: 30015176
[TBL] [Abstract][Full Text] [Related]
33. Development of 1,3,4-oxadiazole thione based novel anticancer agents: Design, synthesis and in-vitro studies.
Yadav N; Kumar P; Chhikara A; Chopra M
Biomed Pharmacother; 2017 Nov; 95():721-730. PubMed ID: 28888209
[TBL] [Abstract][Full Text] [Related]
34. Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis.
Sharma N; Sharma M; Shakeel E; Jamal QMS; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM; Akhtar S
Med Chem; 2018; 14(6):626-640. PubMed ID: 29663896
[TBL] [Abstract][Full Text] [Related]
35. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors.
Ai G; Tian C; Deng D; Fida G; Chen H; Ma Y; Ding L; Gu Y
Anticancer Drugs; 2015 Apr; 26(4):399-409. PubMed ID: 25569705
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
[TBL] [Abstract][Full Text] [Related]
37. α-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway.
Weng WT; Huang SC; Ma YL; Chan HH; Lin SW; Wu JC; Wu CY; Wen ZH; Wang EM; Wu CL; Tai MH
Biochim Biophys Acta; 2014 Jun; 1840(6):1850-60. PubMed ID: 24530634
[TBL] [Abstract][Full Text] [Related]
38. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
Shi L; Zhou J; Wu J; Shen Y; Li X
Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
[TBL] [Abstract][Full Text] [Related]
39. Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: antiangiogenic activity study.
Cao W; Li H; Zhang J; Li D; Acheampong DO; Chen Z; Wang M
Protein Expr Purif; 2013 Aug; 90(2):55-66. PubMed ID: 23680780
[TBL] [Abstract][Full Text] [Related]
40. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
Ruel R; Thibeault C; L'Heureux A; Martel A; Cai ZW; Wei D; Qian L; Barrish JC; Mathur A; D'Arienzo C; Hunt JT; Kamath A; Marathe P; Zhang Y; Derbin G; Wautlet B; Mortillo S; Jeyaseelan R; Henley B; Tejwani R; Bhide RS; Trainor GL; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 May; 18(9):2985-9. PubMed ID: 18395443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]